Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tara L Lin

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
Leukemia & Lymphoma|May 21, 2020
Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemiaEunice S Wang, Richard Aplenc, Deborah Chirnomas, et al.
Cardio-Oncology (London, England)|November 26, 2025
CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysisJoshua D Mitchell, Michael Pfeiffer, John Boehmer, et al.
British Journal of Haematology|September 12, 2018
Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trialDale Bixby, Richard Noppeney, Tara L Lin, et al.
Molecular Cancer Research : MCR|January 30, 2021
Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma CellsSudhakiranmayi Kuravi, Janice Cheng, Gabrielle Fangman, et al.
JCO Oncology Practice|July 1, 2024
North American Cancer Center Clinical Research Capacity and Benchmarking in the Postpandemic EraMargaret Kasner, Angela H Fritsche, Man Chong Leong, et al.
Cardio-Oncology (London, England)|May 23, 2026
Correction: CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysisJoshua D Mitchell, Michael Pfeiffer, John Boehmer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 7, 2019
Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell TransplantationHaitham Abdelhakim, Leyla Shune, Sajjad Bhatti, et al.
Blood Cells, Molecules & Diseases|August 20, 2013
Hyperbaric oxygen improves engraftment of ex-vivo expanded and gene transduced human CD34⁺ cells in a murine model of umbilical cord blood transplantationOmar S Aljitawi, Yinghua Xiao, Jeff D Eskew, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2020
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid LeukemiaAmer M Zeidan, Maya Ridinger, Tara L Lin, et al.
Blood Advances|December 21, 2021
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndromeAaron T Gerds, Bart L Scott, Peter Greenberg, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Leukemia & Lymphoma|May 21, 2020
Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemiaEunice S Wang, Richard Aplenc, Deborah Chirnomas, et al.
Cardio-Oncology (London, England)|November 26, 2025
CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysisJoshua D Mitchell, Michael Pfeiffer, John Boehmer, et al.
British Journal of Haematology|September 12, 2018
Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trialDale Bixby, Richard Noppeney, Tara L Lin, et al.
Molecular Cancer Research : MCR|January 30, 2021
Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma CellsSudhakiranmayi Kuravi, Janice Cheng, Gabrielle Fangman, et al.
JCO Oncology Practice|July 1, 2024
North American Cancer Center Clinical Research Capacity and Benchmarking in the Postpandemic EraMargaret Kasner, Angela H Fritsche, Man Chong Leong, et al.
Cardio-Oncology (London, England)|May 23, 2026
Correction: CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysisJoshua D Mitchell, Michael Pfeiffer, John Boehmer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 7, 2019
Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell TransplantationHaitham Abdelhakim, Leyla Shune, Sajjad Bhatti, et al.
Blood Cells, Molecules & Diseases|August 20, 2013
Hyperbaric oxygen improves engraftment of ex-vivo expanded and gene transduced human CD34⁺ cells in a murine model of umbilical cord blood transplantationOmar S Aljitawi, Yinghua Xiao, Jeff D Eskew, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2020
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid LeukemiaAmer M Zeidan, Maya Ridinger, Tara L Lin, et al.
Blood Advances|December 21, 2021
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndromeAaron T Gerds, Bart L Scott, Peter Greenberg, et al.
Pageof 9